Cytokinetics, Incorporated
- CYTK
- NASDAQ
- Biotechnology
- Muscle Therapies
- Cardiac Drugs
$61.95
Today −3.08%Quote Oct 16, 2026, 08:00 PM UTC
−11.40%over the last month
Max drawdown −12.6%From 1-month high −11.4%3 months −21.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$8.61B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$113.33
+82.9% from here
Floor
$61.02
1.5% below price
Where the price sits
35 analysts
Analyst range, low to high
$103.00$140.00
- Price $61.95
- Resistance $62.82
- Consensus $113.33
The price is just above its floor and right under resistance. Analysts' average target sits about 83% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CYTKPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $31.9M
- Net Product Revenue$25.3M79.4%
- Collaboration Revenues$3.3M10.3%
- Other / not reported$3.3M10.3%
Industry
Biotechnology
Employees
673
Founded
1997